Medpakto Announces MP2021 Breakthrough in Psoriasis Treatment with New Protein Inhibition Study

MedPacto has published research indicating that its drug candidate MP2021 shows potential for treating psoriasis, according to Korean-language news reports published on April 24, 2026. The findings were reported by multiple Korean news outlets including Pharm Edaily, Newsis, and Nate, which cited the company’s announcement of a paper published in an international academic journal.

The reports state that MedPacto’s research suggests that inhibiting a specific protein may enable treatment of psoriasis. MP2021 is described as an innovative drug candidate that functions by blocking osteoclast multinucleation and inhibiting bone differentiation, according to information from MedPacto’s own publications and LinkedIn posts referenced in web search results.

While MP2021’s primary research focus has been on bone diseases such as rheumatoid arthritis and osteoporosis, the company is now investigating its potential application for autoimmune conditions including psoriasis. The drug’s mechanism involves targeting pathways related to immune system signaling that contribute to inflammatory conditions.

Current psoriasis treatments include biologics that target specific immune pathways such as IL-23 and IL-17, as well as oral medications like JAK and TYK2 inhibitors. Recent advances in psoriasis therapy have included drugs such as Guselkumab (Tremfya), Risankizumab (Skyrizi), Tildrakizumab (Ilumya), and newer agents like bimekizumab which targets both IL-17A and IL-17F cytokines.

Oral treatment options for psoriasis include Tofacitinib (Xeljanz), a JAK inhibitor, and emerging TYK2 inhibitors that work by blocking intracellular signaling pathways involved in inflammation. These treatments aim to reduce the immune system overactivity that drives psoriasis symptoms.

The psoriasis treatment landscape continues to evolve as researchers seek alternatives for patients who do not respond adequately to existing therapies or who experience diminished effectiveness over time. Having multiple treatment options targeting different biological pathways allows for personalized approaches based on individual patient response and disease characteristics.

MedPacto’s investigation into MP2021 for psoriasis represents an exploration of whether the drug’s mechanism of action—originally developed for bone-related autoimmune conditions—could be adapted to address the inflammatory processes involved in skin psoriasis. However, the news reports do not specify the stage of research, clinical trial data, or specific protein targets involved in the psoriasis findings.

As with any early-stage drug research, further investigation would be required to determine MP2021’s safety, efficacy, and appropriate dosing for psoriasis treatment before it could be considered for clinical use. The transition from bone disease research to psoriasis application would require validation through appropriate preclinical and clinical studies.

The company’s publication in an international academic journal indicates that the research has undergone peer review, though the specific journal name and publication details were not included in the Korean news reports available through the Google News discovery feed.